Piramal’s Healthcare Vertical Further Expand Commercial ADC Capacity
News Aug 05, 2013
Piramal’s Healthcare vertical has announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.
The upgrade will give Piramal two commercial grade ADC suites at the Grangemouth facility, while retaining clinical phase manufacturing capacity in other suites on site.
ADCs are targeted therapies designed to deliver a drug payload to cancer cells while minimizing the adverse effects on normal healthy cell and Piramal | Healthcare was the first contract supplier of ADCs globally.
The batch size offered from the Grangemouth facility ranges from 1-1.5kg and Piramal has capacity for further expansion on site if required.
As part of the investment, the areas supporting the manufacturing suite will also be upgraded to provide new areas for buffer preparation, equipment preparation and antibody freeze / thaw.
Piramal also intends to expand its “Proof of Concept” (POC) offer at Grangemouth, for pharma companies looking to demonstrate antibody and/or toxin suitability for use as an ADC.
“Piramal was a pioneer when it came to the commercial manufacture of ADCs” commented Aidan Walker, President, Formulation Services. “Continued growth in the ADC market and customer demand have led to this latest investment. As part of our POC offer we draw on our vast experience in ADCs to supply model antibodies, the corresponding target cell lines, and non proprietary toxins, to demonstrate suitability of client materials for use in ADC conjugation. We have worked on over 65 ADC candidates and over 30 different ADC drug linkers to date and also have experience with PEGylation, chelating conjugates for radioimmunotherapy and protein toxin conjugates.”
Vijay Shah, Executive Director & Chief Operating Officer of Piramal Enterprises, added, “This investment, supporting an emerging and exciting platform in the field of oncology treatment, aligns completely with our values as an organization. We view ADCs as a strategic area of growth for our Pharma Solutions Business and this investment demonstrates our intention to support our customers with facilities and capacity that can support them into commercial supply”.
The announcement follows the news in October 2012 that Piramal had formed an alliance with Fujifilm Diosynth Biotechnologies through which the two companies offer seamless contract development and manufacture of ADCs.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE